DOI QR코드

DOI QR Code

Positive Association Between IL-16 rs11556218 T/G Polymorphism and Cancer Risk: a Meta-analysis

  • Mo, Cui-Ju (Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University) ;
  • Peng, Qi-Liu (Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University) ;
  • He, Yu (Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University) ;
  • Wang, Jian (Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University) ;
  • Xie, Li (Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University) ;
  • Li, Tai-Jie (Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University) ;
  • Li, Shan (Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University) ;
  • Qin, Xue (Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University)
  • 발행 : 2014.06.15

초록

Background: Interleukin-16 (IL-16) is a multifunctional cytokine which plays a key role in inflammatory and autoimmune diseases as well as in cancer. Genetic polymorphisms of IL-16 have been implicated in susceptibility to cancer. However, associations remain inconclusive. The present meta-analysis was therefore carried out to establish a more conclusive association of IL-16 polymorphisms with cancer risk. Materials and Methods: Relevant studies were searched through the PubMed, Embase, Web of Science, Google Scholar and Wan fang electronic databases updated in October 2013. Odds ratios (OR) and 95% confidence intervals (95% CI) were used to assess the association between IL-16 polymorphisms and cancer risk. Results: Eight eligible studies (rs4778889 T/C: 8, rs11556218 T/G: 7, rs4072111 C/T: 6) that met our selection criteria were included. The meta-analysis indicated that rs11556218 T/G was associated with a significant increased risk of cancer (G vs. T, OR=1.321, 95% CI=1.142-1.528, P<0.001; TG vs. TT, OR=1.665, 95% CI=1.448-1.915, P<0.001; GG+TG vs. TT, OR=1.622, 95% CI=1.416-1.858, P<0.001),as well as nasopharyngeal carcinoma and colorectal cancer. Furthermore, in the subgroup of Chinese, significant associations were found between rs11556218 polymorphism and cancer risk. There was no statistically significant association between the other two variants (rs4778889, rs4072111) and risk of cancer. Conclusions: This meta-analysis suggests that the IL-16 rs11556218 polymorphism is associated with increased cancer risk. Large well-designed studies involving various cancer types and different populations are now needed.

참고문헌

  1. Alexandrakis MG, Passam FH, Kyriakou DS, et al (2004). Serum level of interleukin-16 in multiple myeloma patients and its relationship to disease activity. Am J Hematol, 75, 101-6. https://doi.org/10.1002/ajh.10444
  2. Almendro V, Marusyk A, Polyak K (2013). Cellular heterogeneity and molecular evolution in cancer. Annu Rev Pathol, 8, 277-302. https://doi.org/10.1146/annurev-pathol-020712-163923
  3. Azimzadeh P, Romani S, Mohebbi SR, et al (2011). Interleukin-16 (IL-16) gene polymorphisms in Iranian patients with colorectal cancer. J Gastrointestin Liver Dis, 20, 371-6.
  4. Azimzadeh P, Romani S, Mohebbi SR, et al (2012). Association of polymorphisms in microRNA-binding sites and colorectal cancer in an Iranian population. Cancer Genet, 205, 501-7. https://doi.org/10.1016/j.cancergen.2012.05.013
  5. Baier M, Bannert N, Werner A, et al (1997). Molecular cloning, sequence, expression, and processing of the interleukin 16 precursor. Proc Natl Acad Sci USA, 94, 5273-7. https://doi.org/10.1073/pnas.94.10.5273
  6. Balkwill F, Mantovani A (2001). Inflammation and cancer: back to Virchow? Lancet, 357, 539-45. https://doi.org/10.1016/S0140-6736(00)04046-0
  7. Batai K, Shah E, Murphy AB, et al (2012). Fine-mapping of IL16 gene and prostate cancer risk in African Americans. Cancer Epidemiol Biomarkers Prev, 21, 2059-68. https://doi.org/10.1158/1055-9965.EPI-12-0707
  8. Bredberg A (2011). Cancer: more of polygenic disease and less of multiple mutations? A quantitative viewpoint. Cancer, 117, 440-5. https://doi.org/10.1002/cncr.25440
  9. Drwinga HL, Toji LH, Kim CH, et al (1993). NIGMS human/rodent somatic cell hybrid mapping panels 1 and 2. Genomics, 16, 311-4. https://doi.org/10.1006/geno.1993.1190
  10. Center DM, Cruikshank W (1982). Modulation of lymphocyte migration by human lymphokines. I. Identification and characterization of chemoattractant activity for lymphocytes from mitogen-stimulated mononuclear cells. J Immunol, 128, 2563-8.
  11. Center DM, Kornfeld HCruikshank WW (1996). Interleukin 16 and its function as a CD4 ligand. Immunol Today, 17, 476-81. https://doi.org/10.1016/0167-5699(96)10052-I
  12. Deng Y, Li RL, Huang XM, et al (2012). Genetic polymorphism of interleukin-16 influences susceptibility of hepatocellular carcinoma. J Practical Medicine, 28, 3910-2.
  13. Du YJ, Yin CJ, Zhu J, et al (2012). Correlation between IL-16 gene- 295 T>C polymorphism and risk of renal cell carcinoma. J CIin Med in Practice, 16, 18-21.
  14. Gao LB, Liang WB, Xue H, et al (2009a). Genetic polymorphism of interleukin-16 and risk of nasopharyngeal carcinoma. Clin Chim Acta, 409, 132-5. https://doi.org/10.1016/j.cca.2009.09.017
  15. Gao LB, Rao L, Wang YY, et al (2009b). The association of interleukin-16 polymorphisms with IL-16 serum levels and risk of colorectal and gastric cancer. Carcinogenesis, 30, 295-9.
  16. Hughes L, Ruth K, Rebbeck TR, et al (2013). Genetic variation in IL-16 miRNA target site and time to prostate cancer diagnosis in African-American men. Prostate Cancer Prostatic Dis, 16, 308-14. https://doi.org/10.1038/pcan.2013.36
  17. Hussain SP, Harris CC (2007). Inflammation and cancer: an ancient link with novel potentials. Int J Cancer, 121, 2373-80. https://doi.org/10.1002/ijc.23173
  18. Jim HS, Park JY, Permuth-Wey J, et al (2012). Genetic predictors of fatigue in prostate cancer patients treated with androgen deprivation therapy: preliminary findings. Brain Behav Immun, 26, 1030-6. https://doi.org/10.1016/j.bbi.2012.03.001
  19. Li S, Deng Y, Chen ZP, et al (2011). Genetic polymorphism of interleukin-16 influences susceptibility to HBV-related hepatocellular carcinoma in a Chinese population. Infect Genet Evol, 11, 2083-8. https://doi.org/10.1016/j.meegid.2011.09.025
  20. Kai H, Kitadai Y, Kodama M, et al (2005). Involvement of proinflammatory cytokines IL-1beta and IL-6 in progression of human gastric carcinoma. Anticancer Res, 25, 709-13.
  21. Kimman M, Norman R, Jan S, et al (2012). The burden of cancer in member countries of the Association of Southeast Asian Nations (ASEAN). Asian Pac J Cancer Prev, 13, 411-20. https://doi.org/10.7314/APJCP.2012.13.2.411
  22. Kovacs E (2001). The serum levels of IL-12 and IL-16 in cancer patients. Relation to the tumour stage and previous therapy. Biomed Pharmacother, 55, 111-6. https://doi.org/10.1016/S0753-3322(00)00023-8
  23. Lin PC, Liu TC, Chang CC, et al (2012). High-resolution melting (HRM) analysis for the detection of single nucleotide polymorphisms in microRNA target sites. Clin Chim Acta, 413, 1092-7. https://doi.org/10.1016/j.cca.2012.03.007
  24. Mantovani A (2005). Cancer: inflammation by remote control. Nature, 435, 752-3. https://doi.org/10.1038/435752a
  25. Mathy NL, Scheuer W, Lanzendorfer M, et al (2000). Interleukin-16 stimulates the expression and production of pro-inflammatory cytokines by human monocytes. Immunology, 100, 63-9. https://doi.org/10.1046/j.1365-2567.2000.00997.x
  26. Muc-Wierzgon M, Nowakowska-Zajdel E, Kokot T, et al (2006). Genetic disregulation of TNF alpha and TNF alpha type II receptors in colon cancer at the II and III stage of disease. J Biol Regul Homeost Agents, 20, 10-4.
  27. Nakayama EE, Wasi C, Ajisawa A, et al (2000). A new polymorphism in the promoter region of the human interleukin-16 (IL-16) gene. Genes Immun, 1, 293-4. https://doi.org/10.1038/sj.gene.6363672
  28. Obara W (2010). Editorial comment to IL-16 polymorphism and risk of renal cell carcinoma: association in a Chinese population. Int J Urol, 17, 707. https://doi.org/10.1111/j.1442-2042.2010.02583.x
  29. Shanmugham LN, Petrarca C, Frydas S, et al (2006). IL-15 an immunoregulatory and anti-cancer cytokine. Recent advances. J Exp Clin Cancer Res, 25, 529-36.
  30. Qin X, Peng Q, Lao XX, et al (2014). The association of interleukin-16 gene polymorphisms with IL-16 serum levels and risk of nasopharyngeal carcinoma in a Chinese population. Tumour Biol, 35, 1917-24. https://doi.org/10.1007/s13277-013-1257-2
  31. Quinn GP, Pal T, Murphy D, et al (2012). High-risk consumers' perceptions of preimplantation genetic diagnosis for hereditary cancers: a systematic review and meta-analysis. Genet Med, 14, 191-200. https://doi.org/10.1038/gim.0b013e31822ddc7e
  32. Sethi G, Shanmugam MK, Ramachandran L, et al (2012). Multifaceted link between cancer and inflammation. Biosci Rep, 32, 1-15. https://doi.org/10.1042/BSR20100136
  33. Thomas G, Jacobs KB, Yeager M, et al (2008). Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet, 40, 310-5. https://doi.org/10.1038/ng.91
  34. van Horssen R, Ten Hagen TL, Eggermont AM (2006). TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist, 11, 397-408. https://doi.org/10.1634/theoncologist.11-4-397
  35. Weiderpass E (2010). Lifestyle and cancer risk. J Prev Med Public Health, 43, 459-71. https://doi.org/10.3961/jpmph.2010.43.6.459
  36. Zhao J, Yang YM, Li QZ (2012). Association between IL-16 polymorphisms and risk of cervical cancer. Chin J Cancer Prev Treat, 19, 1205-20.
  37. Zhang T, Wang H (2013). Variants of interleukin-16 associated with gastric cancer risk. Asian Pac J Cancer Prev, 14, 5269-73. https://doi.org/10.7314/APJCP.2013.14.9.5269
  38. Zhang Y, Center DM, Wu DM, et al (1998). Processing and activation of pro-interleukin-16 by caspase-3. J Biol Chem, 273, 1144-9. https://doi.org/10.1074/jbc.273.2.1144
  39. Zhu J, Qin C, Yan F, et al (2010). IL-16 polymorphism and risk of renal cell carcinoma: association in a Chinese population. Int J Urol, 17, 700-7. https://doi.org/10.1111/j.1442-2042.2010.02559.x

피인용 문헌

  1. Association of Hypoxia-Inducible Factor-2 Alpha Gene Polymorphisms with the Risk of Hepatitis B Virus-Related Liver Disease in Guangxi Chinese: A Case-Control Study vol.11, pp.7, 2016, https://doi.org/10.1371/journal.pone.0158241
  2. Coarse particulate matter (PM2.5–10) in Los Angeles Basin air induces expression of inflammation and cancer biomarkers in rat brains vol.8, pp.1, 2018, https://doi.org/10.1038/s41598-018-23885-3